Loiasis Cross-reactive Antigenemia and Treatment-related Adverse Events

Loiasis Cross-reactive Antigenemia and Treatment-related Adverse Events

This study seeks to determine which Loa loa antigens are released into circulation when infected individuals are treated with ivermectin.

A cohort of up to 50 participants with Loa loa microfilarial levels between 5,000 and 18,000 per ml/blood will be treated with ivermectin in an inpatient setting. Participants will be monitored for treatment-related adverse events for seven days post-treatment, and will have blood drawn on days 0, 1, 2, 3, and 7 post-treatment to assess for microfilarial load, cytokine, and antigen levels.

Inclusion Criteria:

• Loa loa blood microfilariae of between 5,000 - 18,000 per mL

Exclusion Criteria:

• known allergy to ivermectin; severe comorbidities